Keywords: Osiris Thera, Genzyme, Sanofi, Prochymal, Chondrogen, Stem cell products, World rights

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi

Article | 30 September 2012

Print This

As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in